Thymalfasin (thymosin‑alpha‑1) is a peptide that can boost the body’s Th1 immune response and help T‑cells mature, which may improve how the immune system fights viruses and some cancers. The research shows it helped animals with hepatitis, flu, melanoma and colon cancer, and it’s been tested in people with chronic hepatitis B/C, AIDS and weak immune systems, but clear dosing guidelines for everyday use aren’t provided.

Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Th1 immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases, including chronic hepatitis B and C, AIDS, primary immunodeficiency diseases, depressed response to vaccination and cancer. The basis for effectiveness in these conditions is primarily through modulation of immunological responsiveness, as thymalfasin has been shown to have beneficial effects on numerous immune system parameters and to increase T-cell differentiation and maturation. Thymalfasin is responsible for reconstitution of immune function when thymic tissue is given back to thymectomized animals. In addition, thymalfasin has been shown to have efficacy in multiple experimental models of immune dysfunction, mainly, infectious diseases such as hepatitis (woodchuck) and influenza (mouse), and cancer such as melanoma (mouse) and colorectal carcinoma (rat) where thymalfasin has shown antitumor effects.